ArticleFrontiers in immunology2025
Identification and validation of mitochondrial and programmed cell death-related prognostic markers in pediatric acute myeloid leukemia.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric acute myeloid leukemia (AML) is characterized by poor prognosis and low survival rates following recurrence. While mitochondria and programmed cell death (PCD) are implicated in various diseases, their role in pediatric AML remains poorly understood. Identifying prognostic genes associated with PCD and mitochondrial function could enhance therapeutic approaches. Methods: Transcriptomic data and gene sets were sourced from public databases. Differentially expressed genes (DEGs) that intersected with PCD-related genes (PCD-RGs) and mitochondrial-related genes (mito-RGs) were selected as candidate genes. Regression analyses were performed to identify prognostic genes, which were then used to develop and validate a prognostic model. A nomogram was constructed, followed by functional analysis, immune microenvironment assessment, molecular regulatory network investigation, drug sensitivity profiling, and clinical validation through RT-qPCR. Results: Twenty-six candidate genes were identified, with three-PDHA1, OGG1, and OPA1-confirmed as potential prognostic markers through regression analyses. The prognostic model demonstrated robustness in both internal and external validations, and the nomogram exhibited good predictive power. Pathway enrichment analysis highlighted the involvement of DNA replication and epithelial-mesenchymal transition, alongside 14 differentially abundant immune cells (p < 0.05). Molecular network analysis indicated that hsa-miR-199a-5p regulates PDHA1 and OGG1. Drug sensitivity profiling identified potential therapeutic agents, including SB505124_1194. RT-qPCR validation confirmed consistent expression patterns for the prognostic genes. Conclusions: PDHA1, OGG1, and OPA1 were identified as potential prognostic markers for pediatric AML, providing valuable insights for the development of targeted therapeutic strategies. However, further validation in larger and more diverse clinical cohorts is still required to confirm its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.